NewLimit raises $435M Series C to launch epigenetic anti-aging therapy, while Lilly signs GLP-2 obesity drug deal

Longevity startup NewLimit announced a $435 million Series C financing, one of the largest biotech rounds this year. The round was led by Founders Fund and included investors such as Thrive Capital, Greenoaks, Quiet Capital and Eli Lilly Ventures.

The company says the capital will fund its first clinical trial, slated for next year, of a liver-focused epigenetic reprogramming therapy aimed at reversing cellular age.

Eli Lilly continued its active dealmaking week, revealing two new licensing agreements. One partnership with South Korea’s Hanmi Pharma gives Lilly primary rights to an obesity drug that mimics the gut hormone GLP-2.

A second agreement with a Chinese partner was also disclosed, expanding Lilly’s pipeline across multiple therapeutic areas. The announcements came alongside a drop in Praxis Precision Medicines’ share price.